Nanochon, an orthopedic device company, closed a $4.1 million Seed Prime II funding round.
The company is developing an implant for treating cartilage defects in the knee. The funding will be used for its first in-human clinical study for the implant, according to a Jan. 12 cultivate(MD), which led the funding round.
The phase 1 trial will evaluate the efficacy and safety of the company’s Chondrograft knee implant in a 10 patient study.
In total, Nanochon has raised $11.3 million in capital, the release said.
